Developer docs
API playgroundTry for free, no card

Search company profiles

Nabla Bio

Full company profile

uuid00008lb

Namestring
Nabla Bio
Legal namestring
Nabla Bio, Inc
Websiteurl
nabla.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Nabla Bio is a privately held biotechnology company founded in 2020 and based in Cambridge, Massachusetts, that operates a generative AI platform for de novo antibody and biologics design. Its core technology, JAM (Joint Atomic Modeling) and its successor JAM-2, is a proprietary multimodal generative model trained on protein sequence and structure data and reinforced with Nabla-generated, human-relevant wet-lab measurements. JAM takes partial molecular context — such as a disease target or epitope — and "autocompletes" the rest, enabling de novo antibody design, epitope scaffolding, developability and affinity optimization, and the design of developable multispecific architectures. The platform is tightly integrated with mammalian wet-lab systems that produce thousands of protein designs and measure binding, developability, cellular function, and in vivo behavior in human-relevant contexts, with a particular emphasis on hard-to-drug targets such as GPCRs, ion channels, transporters, and multipass membrane proteins.

The company serves large pharmaceutical companies through multi-year research collaborations and a secondary biologics-licensing motion. Disclosed enterprise customers include Takeda Pharmaceutical Company (initial collaboration 2022, expanded October 2025), AstraZeneca, and Bristol Myers Squibb. Reported cumulative deal value across these three partners exceeds $550 million, including a second Takeda deal with potential success-based milestones exceeding $1 billion if all targets advance. Deal economics combine upfront payments, double-digit-million research funding, and milestone-contingent payments. The company also develops an internal portfolio of designed biologics and licenses these to partners with downstream development expertise.

Nabla has raised approximately $37 million in disclosed venture funding — an $11 million seed round in December 2021 (co-led by Khosla Ventures and Zetta Venture Partners) and a $26 million Series A in May 2024 (led by Radical Ventures). The team of 11-50 employees operates fully in-person from a single Cambridge, MA headquarters and is led by co-founders Surge Biswas (CEO), Frances Anastassacos (President), and George Church, with Rose Harrison as Chief Business Officer. Technical claims — including 20-70x higher binding success rates on difficult receptors, sub-nanomolar affinities on CXCR4, and experimentally validated binders on 5 of 9 publicly comparable de novo antibody targets in a May 2026 third-party comparative study — are documented in bioRxiv preprints, technical reports, and Nature-family publications.

Short descriptiontext

Nabla Bio operates a proprietary generative AI platform (JAM/JAM-2) integrated with mammalian wet-lab systems to design drug-like antibodies and multispecifics de novo. It serves large pharmaceutical companies including Takeda, AstraZeneca, and Bristol Myers Squibb through multi-year research collaborations and licensing arrangements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI antibody design, de novo biologics, computational drug design, generative protein engineering, multispecific antibody platform
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Biologics Design Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Multi-year pharma research collaborations
TypeProfessional Services
Description

Nabla enters multi-year research collaborations with large pharmaceutical companies (e.g., Takeda — initial 2022 partnership, expanded October 2025) in which Nabla applies JAM to design antibodies and multispecifics against agreed therapeutic targets. Deal economics include upfront payments, double-digit-million research payments, and success-based milestone payments (Takeda deal: potential milestones exceeding $1B if all targets advance).

firstwordpharma.com
2Licensing of internally designed biologics
TypeLicensing Royalties
Description

Nabla develops a growing portfolio of designed biologics against high-value disease targets and licenses these molecules to partners with downstream development expertise to accelerate the path to patients.

nabla.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
Pricing details2 tiers
1Deal-based research collaboration pricing — upfront + research payments + milestone payments
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Quote-based. Example: Takeda deal — double-digit-million upfront/research payments, plus potential milestone payments exceeding $1 billion if all targets advance successfully.

firstwordpharma.com
2Licensing of internally designed biologics portfolio
ModelOther
Notes

Quote-based. License terms not publicly disclosed.

nabla.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1JAM (Joint Atomic Model)
Description

Nabla's multimodal generative modeling system trained on protein sequence and structure data, used for de novo antibody and multispecific biologics design, epitope scaffolding, developability and affinity optimization.

nabla.bio
+1 more record
Core offering1 text field

Nabla Bio operates an integrated AI-driven drug design platform centered on its proprietary generative modeling system, JAM (Joint Atomic Model) and its next-generation version JAM-2. The platform combines de novo molecular design of antibodies and multispecifics with a tightly integrated mammalian wet-lab testing engine that produces thousands of protein designs and measures binding, developability, and cellular/in vivo function. It is delivered to partners via multi-year research collaborations and the licensing of internally designed biologics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 20-70x higher binding success rates vs previous methods on difficult receptors (GPCRs)
+6 more records
Product overview1 text field

Nabla Bio offers a single integrated AI-driven drug design platform centered on its proprietary generative modeling system, JAM (and its next-generation version JAM-2), paired with an in-house human-relevant wet-lab testing engine. The platform combines de novo molecular design with large-scale experimental biology — the JAM/JAM-2 models take partial molecular context (e.g., a disease target or epitope) and design antibodies, multispecifics, and other biologics, while Nabla's wet-lab systems produce thousands of designs in mammalian systems and measure binding, developability, and function. Together, JAM, JAM-2, the wet-lab engine, and the licensing portfolio of designed biologics form the company's full offering, delivered to partners via research collaborations (e.g., Takeda, AstraZeneca, Bristol Myers Squibb) and licensing arrangements.

Product and service4 records
1JAM (Joint Atomic Model)
CategoryCore AI Platform
Description

Multimodal generative modeling system trained on massive protein sequence and structure data and strengthened with Nabla-generated human-relevant measurements. Takes partial molecular context such as a disease target or epitope and 'autocompletes' the rest, enabling de novo biologics design, epitope scaffolding/presentation, developability and affinity optimization, and rapid generation of developable multispecific architectures.

2JAM-2
CategoryCore AI Platform
Description

Next-generation version of JAM that generates drug-like antibodies straight from the computer. Achieves binding success rates 20-70x higher than previous methods and was used to discover the first antibody activators for CXCR7 and hundreds of functional GPCR-targeting antibodies.

3Human-Relevant Data Generation / Wet-Lab Testing Engine
CategoryIntegrated Wet-Lab Component
Description

Nabla's in-house experimental systems produce thousands of protein designs in mammalian systems and measure binding, developability properties, and function in cellular and in vivo contexts that closely reflect human biology, generating the integrated data that sharpens JAM's ability to design drug-like molecules from the start.

4Designed Biologics Portfolio (Licensing)
CategoryLicensing Offering
Description

Growing portfolio of Nabla-designed biologics against high-value disease targets (including antibodies and multispecifics), which Nabla licenses to partners with deep development expertise to accelerate their path to patients.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Multi-year research collaboration to develop AI-driven protein therapeutics, including antibodies and multispecifics, using Nabla's Joint Atomic Model (JAM) platform. Builds on an initial 2022 collaboration. Nabla receives upfront and double-digit-million research payments plus potential success-based milestone payments exceeding $1 billion if all targets advance successfully.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-18
Description

Disclosed pharma partnership contributing to Fast Company-reported $550M+ cumulative deal value across AstraZeneca, Bristol Myers Squibb, and Takeda. Logo appears on nabla.bio partner block alongside Takeda and BMS.

3Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-18
Description

Disclosed pharma partnership contributing to Fast Company-reported $550M+ cumulative deal value across AstraZeneca, Bristol Myers Squibb, and Takeda. Logo appears on nabla.bio partner block alongside Takeda and AstraZeneca.

fastcompany.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based AI-driven antibody discovery company combining machine learning with automated wet-lab experimentation. Frequently grouped with Nabla in industry coverage as a competing next-gen antibody design platform.

TypeDirect peer
Description

AI-first drug discovery company applying foundation models to antibody and protein design, launched with >$1B in funding. A leading direct competitor pursuing similar pharma partnerships and internal pipeline development.

TypeDirect peer
Description

Public AI drug creation company building generative AI models for de novo antibody design paired with high-throughput wet-lab validation. Competes head-to-head with Nabla for pharma collaboration deals on novel biologics.

TypeDirect peer
Description

Generative biology company developing de novo protein therapeutics across antibodies, enzymes, and peptides. Sells into pharma via partnerships and is consistently cited alongside Nabla as a leader in generative antibody design.

TypeDirect peer
Description

AI-driven protein and antibody design platform that emerged as a direct competitor; Chai-2 was benchmarked against Nabla's JAM-2 in a third-party study (4/9 vs 5/9 targets), confirming comparable product scope and target customer (pharma partners).

TypeBroad incumbent
Description

Public computational chemistry and biology platform with a growing biologics design offering and established pharma software footprint. Overlaps with Nabla in computational antibody and protein design at pharma customers.

TypeEmerging player
Description

AI protein engineering company using generative models to optimize protein properties for biotech and pharma partners. Comparable in applying generative AI to protein design with a partnership-led GTM, though focused on a broader set of protein classes.

TypeBroad incumbent
Description

Public AI-driven drug discovery company pairing high-throughput wet-lab experimentation with foundation models. Operates in adjacent — and partially overlapping — AI biologics discovery territory with Nabla.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company applying DeepMind's AlphaFold-derived capabilities to therapeutic design. A broader, well-capitalized incumbent with overlapping ambitions in AI-driven protein and antibody engineering.

TypeEmerging player
Description

Korean AI protein design company whose GaluxDesign platform topped the third-party benchmark at 8/9 targets versus Nabla's 5/9. Emerging competitor with strong published de novo antibody design results.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nabla Bio

AI Biologics Design Platformnabla.bio

Nabla Bio operates a proprietary generative AI platform (JAM/JAM-2) integrated with mammalian wet-lab systems to design drug-like antibodies and multispecifics de novo. It serves large pharmaceutical companies including Takeda, AstraZeneca, and Bristol Myers Squibb through multi-year research collaborations and licensing arrangements.

What Nabla Bio does

Nabla Bio is a privately held biotechnology company founded in 2020 and based in Cambridge, Massachusetts, that operates a generative AI platform for de novo antibody and biologics design. Its core technology, JAM (Joint Atomic Modeling) and its successor JAM-2, is a proprietary multimodal generative model trained on protein sequence and structure data and reinforced with Nabla-generated, human-relevant wet-lab measurements. JAM takes partial molecular context — such as a disease target or epitope — and "autocompletes" the rest, enabling de novo antibody design, epitope scaffolding, developability and affinity optimization, and the design of developable multispecific architectures. The platform is tightly integrated with mammalian wet-lab systems that produce thousands of protein designs and measure binding, developability, cellular function, and in vivo behavior in human-relevant contexts, with a particular emphasis on hard-to-drug targets such as GPCRs, ion channels, transporters, and multipass membrane proteins.

The company serves large pharmaceutical companies through multi-year research collaborations and a secondary biologics-licensing motion. Disclosed enterprise customers include Takeda Pharmaceutical Company (initial collaboration 2022, expanded October 2025), AstraZeneca, and Bristol Myers Squibb. Reported cumulative deal value across these three partners exceeds $550 million, including a second Takeda deal with potential success-based milestones exceeding $1 billion if all targets advance. Deal economics combine upfront payments, double-digit-million research funding, and milestone-contingent payments. The company also develops an internal portfolio of designed biologics and licenses these to partners with downstream development expertise.

Nabla has raised approximately $37 million in disclosed venture funding — an $11 million seed round in December 2021 (co-led by Khosla Ventures and Zetta Venture Partners) and a $26 million Series A in May 2024 (led by Radical Ventures). The team of 11-50 employees operates fully in-person from a single Cambridge, MA headquarters and is led by co-founders Surge Biswas (CEO), Frances Anastassacos (President), and George Church, with Rose Harrison as Chief Business Officer. Technical claims — including 20-70x higher binding success rates on difficult receptors, sub-nanomolar affinities on CXCR4, and experimentally validated binders on 5 of 9 publicly comparable de novo antibody targets in a May 2026 third-party comparative study — are documented in bioRxiv preprints, technical reports, and Nature-family publications.

Nabla Bio firmographics

Firmographics
Name
Nabla Bio
Legal name
Nabla Bio, Inc
Website
https://nabla.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Nabla Bio operates a proprietary generative AI platform (JAM/JAM-2) integrated with mammalian wet-lab systems to design drug-like antibodies and multispecifics de novo. It serves large pharmaceutical companies including Takeda, AstraZeneca, and Bristol Myers Squibb through multi-year research collaborations and licensing arrangements.
Ownership category
akta.pro rank

Nabla Bio industry classification

Industry
Product category
AI Biologics Design Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI antibody design
  • De novo biologics
  • Computational drug design
  • Generative protein engineering
  • Multispecific antibody platform

Where Nabla Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Nabla Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Multi-year pharma research collaborations: Nabla enters multi-year research collaborations with large pharmaceutical companies (e.g., Takeda — initial 2022 partnership, expanded October 2025) in which Nabla applies JAM to design antibodies and multispecifics against agreed therapeutic targets. Deal economics include upfront payments, double-digit-million research payments, and success-based milestone payments (Takeda deal: potential milestones exceeding $1B if all targets advance).
  2. Licensing of internally designed biologics: Nabla develops a growing portfolio of designed biologics against high-value disease targets and licenses these molecules to partners with downstream development expertise to accelerate the path to patients.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformanceMulti-year contractDeal-based research collaboration pricing — upfront + research payments + milestone payments
Other—Licensing of internally designed biologics portfolio

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Nabla Bio product offering

Product offering

Core offering

Nabla Bio operates an integrated AI-driven drug design platform centered on its proprietary generative modeling system, JAM (Joint Atomic Model) and its next-generation version JAM-2. The platform combines de novo molecular design of antibodies and multispecifics with a tightly integrated mammalian wet-lab testing engine that produces thousands of protein designs and measures binding, developability, and cellular/in vivo function. It is delivered to partners via multi-year research collaborations and the licensing of internally designed biologics.

Product overview

Nabla Bio offers a single integrated AI-driven drug design platform centered on its proprietary generative modeling system, JAM (and its next-generation version JAM-2), paired with an in-house human-relevant wet-lab testing engine. The platform combines de novo molecular design with large-scale experimental biology — the JAM/JAM-2 models take partial molecular context (e.g., a disease target or epitope) and design antibodies, multispecifics, and other biologics, while Nabla's wet-lab systems produce thousands of designs in mammalian systems and measure binding, developability, and function. Together, JAM, JAM-2, the wet-lab engine, and the licensing portfolio of designed biologics form the company's full offering, delivered to partners via research collaborations (e.g., Takeda, AstraZeneca, Bristol Myers Squibb) and licensing arrangements.

Differentiator

Problem solved

Functional benefit

Brands

  • JAM (Joint Atomic Model): Nabla's multimodal generative modeling system trained on protein sequence and structure data, used for de novo antibody and multispecific biologics design, epitope scaffolding, developability and affinity optimization.
  • JAM-2

Products and services

  • JAM (Joint Atomic Model) Multimodal generative modeling system trained on massive protein sequence and structure data and strengthened with Nabla-generated human-relevant measurements. Takes partial molecular context such as a disease target or epitope and 'autocompletes' the rest, enabling de novo biologics design, epitope scaffolding/presentation, developability and affinity optimization, and rapid generation of developable multispecific architectures.
  • JAM-2 Next-generation version of JAM that generates drug-like antibodies straight from the computer. Achieves binding success rates 20-70x higher than previous methods and was used to discover the first antibody activators for CXCR7 and hundreds of functional GPCR-targeting antibodies.
  • Human-Relevant Data Generation / Wet-Lab Testing Engine Nabla's in-house experimental systems produce thousands of protein designs in mammalian systems and measure binding, developability properties, and function in cellular and in vivo contexts that closely reflect human biology, generating the integrated data that sharpens JAM's ability to design drug-like molecules from the start.
  • Designed Biologics Portfolio (Licensing) Growing portfolio of Nabla-designed biologics against high-value disease targets (including antibodies and multispecifics), which Nabla licenses to partners with deep development expertise to accelerate their path to patients.

Quantifiable outcome

  • 20-70x higher binding success rates vs previous methods on difficult receptors (GPCRs)
  • +6 more outcomes

Companies that use Nabla Bio

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Nabla Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Nabla Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Takeda Pharmaceutical CompanyflagshipStrategic or Co-development Partner · 14 October 2025Multi-year research collaboration to develop AI-driven protein therapeutics, including antibodies and multispecifics, using Nabla's Joint Atomic Model (JAM) platform. Builds on an initial 2022 collaboration. Nabla receives upfront and double-digit-million research payments plus potential success-based milestone payments exceeding $1 billion if all targets advance successfully.
  • AstraZenecacoreStrategic or Co-development Partner · 18 March 2025Disclosed pharma partnership contributing to Fast Company-reported $550M+ cumulative deal value across AstraZeneca, Bristol Myers Squibb, and Takeda. Logo appears on nabla.bio partner block alongside Takeda and BMS.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 18 March 2025Disclosed pharma partnership contributing to Fast Company-reported $550M+ cumulative deal value across AstraZeneca, Bristol Myers Squibb, and Takeda. Logo appears on nabla.bio partner block alongside Takeda and AstraZeneca.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Nabla Bio competitors and assessment

Company assessment

Direct peers

  • LabGenius: UK-based AI-driven antibody discovery company combining machine learning with automated wet-lab experimentation. Frequently grouped with Nabla in industry coverage as a competing next-gen antibody design platform.
  • Xaira Therapeutics: AI-first drug discovery company applying foundation models to antibody and protein design, launched with >$1B in funding. A leading direct competitor pursuing similar pharma partnerships and internal pipeline development.
  • Absci: Public AI drug creation company building generative AI models for de novo antibody design paired with high-throughput wet-lab validation. Competes head-to-head with Nabla for pharma collaboration deals on novel biologics.
  • Generate:Biomedicines: Generative biology company developing de novo protein therapeutics across antibodies, enzymes, and peptides. Sells into pharma via partnerships and is consistently cited alongside Nabla as a leader in generative antibody design.
  • Chai Discovery: AI-driven protein and antibody design platform that emerged as a direct competitor; Chai-2 was benchmarked against Nabla's JAM-2 in a third-party study (4/9 vs 5/9 targets), confirming comparable product scope and target customer (pharma partners).

Broad incumbents

  • Schrödinger: Public computational chemistry and biology platform with a growing biologics design offering and established pharma software footprint. Overlaps with Nabla in computational antibody and protein design at pharma customers.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company pairing high-throughput wet-lab experimentation with foundation models. Operates in adjacent — and partially overlapping — AI biologics discovery territory with Nabla.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's AlphaFold-derived capabilities to therapeutic design. A broader, well-capitalized incumbent with overlapping ambitions in AI-driven protein and antibody engineering.

Emerging players

  • Cradle Bio: AI protein engineering company using generative models to optimize protein properties for biotech and pharma partners. Comparable in applying generative AI to protein design with a partnership-led GTM, though focused on a broader set of protein classes.
  • Galux: Korean AI protein design company whose GaluxDesign platform topped the third-party benchmark at 8/9 targets versus Nabla's 5/9. Emerging competitor with strong published de novo antibody design results.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nabla Bio social profiles

Digital presence

Nabla Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nabla Bio leadership team

Management profile

Number of profiles

Profiles4 records

Nabla Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nabla Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nabla Bio

What does Nabla Bio do?

Nabla Bio operates an integrated AI-driven drug design platform centered on its proprietary generative modeling system, JAM (Joint Atomic Model) and its next-generation version JAM-2. The platform combines de novo molecular design of antibodies and multispecifics with a tightly integrated mammalian wet-lab testing engine that produces thousands of protein designs and measures binding, developability, and cellular/in vivo function. It is delivered to partners via multi-year research collaborations and the licensing of internally designed biologics.

Is Nabla Bio a public or private company?

Nabla Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nabla Bio founded?

Nabla Bio was founded in 2020. It employs 11 to 50 people.

Where is Nabla Bio based?

Nabla Bio is headquartered in Cambridge, United States, in the North America region.

How does Nabla Bio make money?

Two revenue lines are on record. Multi-year pharma research collaborations are the primary driver. The others are licensing of internally designed biologics.

Who are Nabla Bio's main competitors?

Direct peers on record are LabGenius, Xaira Therapeutics, Absci, Generate:Biomedicines and Chai Discovery. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Emerging players are Cradle Bio and Galux.

Does Nabla Bio have an API?

No public API is recorded for Nabla Bio.

What industry is Nabla Bio in?

Nabla Bio's product category is AI Biologics Design Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Crypto BriefingNabla Bio expects human trials of AI-designed antibody drugs within two yearsNabla Bio, an OpenAI-backed biotech, expects first-in-human trials of AI-designed antibody drugs within two years. Its JAM-2 model generated candidates against 26 targets, with over 50% meeting developability criteria. The company expanded its Takeda partnership, with potential milestone payments exceeding $1B.GenengnewsNovel Antibody Technologies Strive for Clinical ImpactIndustry investment in antibody-drug conjugate (ADC) technologies has surged since the 2019 approval of Enhertu, with companies now pushing further by optimizing payload potency, improving linker chemistry, and designing novel antibodies to transform cancer treatment outcomes. Lisata Therapeutics presented data at the November 2025 World ADC San Diego conference showing its certepetide cyclic peptide improved ADC efficacy and tumor distribution when combined with cytotoxic payloads, while Genentech demonstrated that degrader-antibody conjugates (DACs) can enable sustained in-vivo activity for previously inactive molecules. AI-driven de novo antibody design companies Nabla Bio and Chai Discovery announced advances achieving double-digit hit rates compared to traditional methods that yield less than one percent success.Singularity HubAI-Designed Antibodies Are Racing Toward Clinical TrialsGenerate:Biomedicines presented promising Phase 1 clinical data in late September for an AI-designed antibody treatment for asthma, showing that a twice-yearly injection reduced asthma-triggering proteins without notable side effects, and subsequently launched a large Phase 3 trial involving approximately 1,600 patients with severe asthma globally. Academic labs and commercial companies including Nabla Bio are racing to develop generative AI tools that can design entirely new antibodies from scratch, with the latest algorithms now capable of modeling intricate protein structures and binding pockets that were previously inaccessible. Researchers report that AI antibody design is shifting from an impossible goal to a routine practice, potentially enabling drugs to target previously "undruggable" proteins, though challenges around immune responses to unfamiliar synthetic proteins remain.IntuitionLabsRLHF in Drug Discovery Models: Architecture & QA ExplainedResearchers and industry have begun adapting Reinforcement Learning from Human Feedback (RLHF) — originally developed for aligning large language models — to molecular design and drug discovery, using expert feedback from medicinal chemists to train reward models that guide generative or optimization policies. The report details RLHF architecture components including preference data collection, reward model training, and policy optimization via Proximal Policy Optimization (PPO), and presents empirical evidence that RLHF approaches substantially improve molecular generation quality, with DrugGen achieving 100% chemically valid molecules versus 95.5% baseline. Case studies examined include Insilico Medicine's GENTRL and ReLEHF initiatives, Eli Lilly's TuneLab platform, and the Nabla Bio–Takeda AI drug design partnership, highlighting a broader industry shift toward human-in-the-loop AI-driven pharmaceutical research.AionlabsSummarizing Pharma-Biotech Deals 2025The article analyzes four major trends driving biopharma deals in 2025: AI integration in drug discovery (with deals like Takeda-Nabla Bio worth up to $1B, Merck KGaA-Valo Health up to $3B, and Roche-Manifold Bio up to $2B), mega-acquisitions in metabolic and obesity treatments (including Pfizer-Metsera at $7B and Novo Nordisk-Akero at $5.2B), strategic platform acquisitions (Novartis-Avidity Biosciences at $12B and BMS-Orbital at $1.5B), and the emergence of Chinese biotech as a key innovation hub (with Western companies investing approximately $66B in Chinese-developed assets). The analysis of 260 deals totaling nearly $280B in disclosed value identifies oncology, immunology, and metabolic disorders as the leading therapeutic areas, while Eli Lilly led by deal count with 24 transactions, nearly double that of Sanofi and Novartis.NatureWhat will be the first AI-designed drug? These disease-fighting antibodies are top contendersScientists have achieved major progress in using AI to design antibody drugs from scratch, a year after the initial proof-of-concept breakthrough. Multiple teams, including researchers at Nabla Bio and Chai Discovery, have successfully generated full-length antibodies with drug-like properties that recognize disease targets at potencies comparable to commercial antibody drugs. These advances could accelerate the timeline for AI-designed therapeutic antibodies to enter clinical trials.Endpoints NewsNabla Bio's AI-made antibodies look more and more ready for prime timeNabla Bio has released the newest version of its flagship AI model, which is generating antibodies that increasingly resemble viable drug candidates. The company is showing early indications of progress in developing these AI-made therapies for potential medical use.World Pharma TodayNabla & Takeda Expand Partnership on AI In Drug DevelopmentNabla Bio, a U.S. biotech firm, signed a second major research partnership with Takeda Pharmaceutical on October 14, 2025, expanding their use of AI in drug development, building on a 2022 collaboration. Under the multi-year agreement, Nabla will receive upfront and research cost payments in double-digit millions and is eligible for success-based payments exceeding $1 billion, while using its proprietary Joint Atomic Model (JAM) AI platform to design protein-based therapeutics for Takeda's early-stage pipeline targeting hard-to-treat diseases. The deal follows Takeda's recent decision to exit cell therapy research to focus on faster, more scalable drug types, with the first-in-human data from AI-designed molecules expected within one to two years.YahooTakeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla BioTakeda Pharmaceutical Company and US biotechnology company Nabla Bio signed a major research partnership on October 14 to deepen the use of AI for accelerating drug delivery, building on an earlier collaboration launched in 2022. As part of the agreement, Takeda will pay an upfront payment in double-digit millions to Nabla, which is eligible for success-based payments exceeding $1 billion. Nabla will use its proprietary AI platform called the Joint Atomic Model (JAM) to design protein-based treatments for Takeda's early-stage pipeline.ReutersUS biotech Nabla Bio, Japan's Takeda expand AI drug design partnershipNabla Bio and Takeda signed a second AI drug design partnership, with Nabla receiving upfront and research cost payments in double-digit millions and eligible for success-based payments exceeding $1 billion. The deal uses Nabla's JAM platform to design protein-based therapeutics for Takeda's early-stage pipeline, with first-in-human data expected within one to two years.